About Multiple Sclerosis Foundation



Home > Learn About Multiple Sclerosis > News > Protein regulator may play inflammation role

Protein regulator may play inflammation role

1/27/2016

A new study describes a protein regulator known as Trabid as an important piece of the puzzle that leads to autoimmune inflammation of the central nervous systems in multiple sclerosis patients. Researchers believe that Trabid and Jmjd2d may be potential therapeutic targets for the treatment of inflammatory diseases such as MS.

Researchers, led by Shao-Cong Sun, professor of Immunology at the University of Texas MD Anderson Cancer Center, found that deletion of a protein-coding gene known as Zranb1, which encodes Trabid, in dendritic cells inhibited expression of IL-12 and IL-23, impairing differentiation of inflammatory T-cells. The process protected study mice from autoimmune inflammation.

Cytokines are small proteins important for cell signaling, and IL-12 and IL-23 are mediators of inflammation and associated with inflammatory diseases. Pro-inflammatory cytokines like IL-12 and IL-23 connect innate responses and immune responses and are also involved in autoimmune and inflammatory diseases, said the researchers. The innate immune system, also known as the nonspecific immune system, is an important subsystem of the overall immune system that comprises the cells and mechanisms that defend the host from infection by other organisms.

Study results were published in the online issue of Nature Immunology.



  Support the MSF
Supporting MSF's programs to help make "a brighter tomorrow" has never been easier.
make a donation 

  Learn About MS
Common symptoms of MS include fatigue, weakness, spasticity, balance problems, bladder and bowel problems, numbness, vision loss, tremors and depression.
learn more 

 

Unless otherwise specified, all medical content is compiled by MSF staff and reviewed for accuracy by a member of our Medical Advisory Board.

The MSF strives to present clear and unbiased information. This site is partially funded through a grant from Bayer Healthcare, LLC.

© Copyright 2000-2013 Multiple Sclerosis Foundation - All Rights Reserved

�